PharmaJet ®, a company focused on improving the performance and outcomes of injectables through needle-free injection technology, announced that its partner, Brazilian Tuberculosis Research Network ...
5 million Needle-free PharmaJet Tropis ® ID syringes are being provided for polio immunization campaigns. Published results show that the Tropis System is a preferred and effective solution to help ...
GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet ®, the maker of innovative, needle-free injection technology, today announced that its partner, Zydus Cadila, has received the Emergency Use Authorization ...
With over 20 million Tropis ID injections supplied globally, PharmaJet is making important contributions to the Global Polio ...
PharmaJet® to Highlight the Benefits of Intradermal Needle-free Delivery and Expansion into the Self-Injection Pen Market at Upcoming PODD Conference PharmaJet will deliver two presentations on ...
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration ...
The MarketWatch News Department was not involved in the creation of this content. -- PharmaJet's Needle-free intradermal (ID) injection device ("Tropis(R) ID") will be evaluated as delivery system for ...
PharmaJet’s Needle-free intradermal (ID) injection device (“Tropis® ID”) will be evaluated as delivery system for the tuberculin skin test (TST) in a clinical study conducted by REDE-TB. The study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results